Dual inhibitor studies were performed to examine the interaction of aphidicolin, phosphonoformate, 9-(2-hydroxyethoxymethyl)guanine triphosphate, and 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate with herpes simplex virus DNA polymerase. Kinetic data indicated that inhibition by one agent prevents simultaneous inhibition by a second agent, producing a mutually exclusive inhibition pattern. This suggested that binding sites on the DNA polymerase molecule for these compounds are kinetically overlapping. These findings should be taken into consideration for the design of future antiviral compounds and combination chemotherapy protocols.
Herpes simplex virus (HSV) DNA polymerase is a logical target for the development of antiviral drugs since it is necessary for viral replication and is biochemically distinct from host DNA polymerases. Several classes of antiherpetic agents have been developed which interact with virus DNA polymerase. They can be grouped according to mechanism of interaction as follows. (i) The first group is nucleoside analogs; these compounds are phosphorylated in virus-infected cells and interact with virus DNA polymerase as nucleoside triphosphates (NTPs) by competing with naturally occurring deoxynucleoside triphosphates (dNTPs) as substrate for incorporation into replicating DNA. The nucleosides 9-(2-hydroxyethoxymethyl)guanine (ACG; acyclovir) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) are examples which, as NTPs (ACGTP and DHPGTP), compete with dGTP for incorporation into DNA (10, 12, 15, 17) . (ii) Aphidicolin and its derivatives make up the second group; aphidicolin has been found to competitively inhibit incorporation of dATP, dCTP, and dTTP by virus DNA polymerase into activated DNA template (13) , but is noncompetitive with dGTP and uncompetitive with low concentrations. of DNA (13, 21) . (iii) Pyrophosphate analogs constitute the third group; compounds such as phosphonoacetate and its cogener phosphonoformate (PFA) inhibit pyrophosphorolysis competitively with pyrophosphate but are noncompetitive with dNTPs and uncompetitive with DNA (9, 11, 20, 22) .
It appears that these three classes of compounds interact with virus DNA polymerase by different mechanisms. Several laboratories have investigated the inhibition of virus replication in culture by combinations of these compounds. In the case of phosphonoacetate and ACG, antiviral synergism has been observed (7, 26) . Other studies indicate that resistance to PFA can result in both collateral hypersensitivity to aphidicolin (2, 4, 18) and cross-resistance to ACG (5, 6, 8, 14, 19, 24) . It is not clear why resistance to one class of compound affects resistance to a different class of compound. One possibility is that binding sites on the DNA polymerase molecule for these compounds are closely associated. To investigate this possibility, we examined the * Corresponding author. Substrate preparation. ACG was converted to the triphosphate by chemical methods (23) , and DHPG was converted to the triphosphate by using HSV type 1 thymidine kinase and human erythrocyte lysate as described previously (3). NTPs were purified by anion-exchange high-pressure liquid chromatography. Activated DNA was prepared as previously described (1) and end labeled by incubation with [3H]dGTP (6 x 103 cpm/pmol) and HSV DNA polymerase (10) . Reactions were terminated by heating to 65°C for 15 min, followed by slow cooling to 23°C. Unincorporated dNTP was separated from polynucleotide by Sephadex G-25 filtration. Substrate prepared in this manner had 7 x 103 cpm/,ug of nucleotide.
Enzyme purification and assay. DNA polymerase induced by HSV type 1 (KOS) was purified by DEAE, phosphocellulose, and double-stranded DNA-cellulose chromatography as previously described (8) . The specific activity of enzyme used in these studies was at least 1.2 x 104 U/mg. Standard HSV DNA polymerase reaction mixtures contained the following: 50 mM Tris-hydrochloride, pH 8.0; 4 mM MgCI2; 0.5 mM dithiothreitol; 0.2 mg of bovine serum albumin per ml; 0.2 M KCl; 10 ,ug of activated calf thymus DNA; 100 ,uM each dATP, dCTP, and dGTP; and 5 ,uM [3H]dTTP in a volume of 100 ,ul. One unit of DNA polymerase activity is defined as the amount of enzyme catalyzing the incorporation of 1 nmol of dTMP per h at 37°C in the standard assay. (0) together, since mutually exclusive kinetics could result from allosteric effects. However, if the binding sites are overlapping it would be possible for a single change at the active site of DNA polymerase to result in altered affinities for PFA, aphidicolin, and acyclic NTPs; for example, if a basic amino acid at the active site is involved in the binding of PFA and acyclic NTP, it is conceivable that a change to a more neutral amino acid would lessen the binding affinities of acidic compounds such as phosphonoacetate and acyclic NTPs, whereas affinities to hydrophobic compounds such as aphidicolin would increase. In this event, the reported cross-resistance of PFA-resistant virus strains and DNA polymerases isolated from these strains to inhibition by acyclic nucleotide (5, 6, 8, 14, 19, 24 ) and collateral hypersensitivity to aphidicolin (2, 4, 18) would be more than coincidental.
Based on the mutually exclusive interaction of PFA, aphidicolin, and acyclic NTP with virus DNA polymerase, we would predict that inhibition of virus by combinations of these compounds should not be more than additive. However, several reports have indicated synergistic interaction of PFA and ACG (7, 26) . One possible explanation for these observations is that these compounds may act by other mechanisms in addition to inhibition of HSV DNA polymerase. There is no evidence at present to support this. It is also possible that the synergistic antiviral activity, which was observed using plaque reduction assays, reflects the action of combinations of these compounds against different populations of virus variants in the virus preparations used. It will be of interest to see if similar results are obtained with yield reduction assays.
The kinetic data presented in these studies suggest that the binding sites for these compounds could be physically overlapping. High-resolution mapping of drug resistance loci of the HSV DNA polymerase gene or sequencing of enzyme 
